Valuation
- Market cap
- 2,615,000
- Revenue TTM
- $0
- Net income TTM
- $-10,350,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 780,200
- Avg volume
- 6,710,262
- Day's range
- $0.15 – $0.18
- Shares out
- 14,693,000
- Stochastic %K
- 22%
- Beta
- 1.70
- Analysts
- Strong Buy
- Price target
- $50.00
Company profile
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of...
Show more
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, identifies and develops pharmaceutical products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nanocrystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT2203, an oral formulation of amphotericin B that is starting Phase 3 clinical trials for the treatment of aspergillosis and cryptococcosis, as well as prevention of invasive fungal infections in patients due to immunosuppressive therapy. It offers MAT2501, an orally administered formulation of amikacin. The company was incorporated in 2013 and is based in Bedminster, New Jersey.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 908 484 8805
- Website
- https://www.matinasbiopharma.com
- Address
- 1545 Route 206 South, Suite 302, Bedminster, United States
Latest news
No headlines yet.
